O-26: Association of Follicular Fluid Endocrine Changes with Oocyte Morphology and Quality in PCOS Patients Undergoing Metformin and N-Acetylcysteine Treatment

Authors

  • Ebrahimi Z
  • Shariatzadeh MA
  • Soleimani M
Abstract:

Background: Polycystic ovary syndrome (PCOS) is a common cause of infertility often responsive to treatment with oral ovulation induction agents. PCOS patients are typically characterized by producing an increased number of oocytes that they are often of poor quality, leading to lower fertilization, cleavage and implantation rates. Recently data involve functional associations between endocrine/paracrine irregularities, metabolic dysfunction and changes in the intrafollicular microenvironment during folliculogenesis, follicle maturation in women with PCOS. In the present study, we have evaluated association of follicular fluid(FF) endocrine changes with oocyte morphology and Quality in PCOS Patients undergoing Metformin and N-acetylcysteine treatment. Materials and Methods: A prospective randomized, placebo controlled experimental study was conducted in the IVF/ICSI Unit of infertility treatment center of the Qom. Total 80 cases between the age of 25 and 35 years of polycystic ovarian syndrome were selected for the study, 20 cases in each group were treated for six weeks with Metformin (500 mg three times daily), with N-acetyl cysteine (600 mg three times daily), with Nacetyl cysteine plus Metformin and with Placebo (Group Control). Before oocyte aspiration, follicular fluid was sampled and carefully collected from the first aspiration follicle of each ovary. The endocrine and hormonal parameters evaluated that including levels of fasting insulin, LH, E2, DHEA-S, TT, AMH, leptin and MDA in follicular fluid in each of the four patients groups. Results: After treatment levels of follicular fluid leptin were significantly differences in the treatment groups compared with placebo group, and only levels of follicular fluid insulin and LH were significantly differences in the MET and NAC group compared with placebo group. Data showed that rates of immature oocytes, fertilization and embryo quality between exprimental groups were statistically significant differences. There were 47.4% of the MII oocytes that had abnormality in Placebo group, while there were 24.5, 34.9 and 39.7% of the MII oocytes that had abnormality in groups NAC, MET and MET+NAC groups, respectively. Also, there were significant correlation between of oocytes retrieved, oocyte quality and maturity, fertilization rate, embryo quality with endocrine variables of follicular fluid in PCOS patients. Conclusion: In the present study, we suggest metformin and NAC promoted endocrine and hormonal levels, improvement of oocyte maturation and quality and ovulation of women with PCOS. Taking its lack of adverse effects into consideration, NAC can be regarded as an appropriate substitute for insulin- reducing medications in the treatment of PCOS patients.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

P-190: Expression Changes of GDF- 9 and BMP-15 in The Oocytes of PCOS Patients Undergoing Treatment with N-acetylcysteine

Background: Polycystic ovary syndrome (PCOS) is a frustrating experience for women, considered as a complex challenge for researchers and clinicians. Despite the enormous effort to define the cause of PCOS, the etiology and pathogenesis still remain unclear. Oocyte quality is reflected in the oocyte’s intrinsic developmental potential. Studies have shown that the follicular development is disru...

full text

Level of Vitamin E in Follicular Fluid and Serum and Oocyte Morphology and Embryo Quality in Patients Undergoing IVF Treatment

Objective: This study aimed to determine the relationship between vitamin E in the follicular fluid (FF) and serum with oocyte morphology and embryo quality. Materials and methods: A cross-sectional study was conducted on serum samples, FF samples, oocytes, and embryos collected from 50 women undergoing in vitro fertilization in the Alzahra Hospital, Rasht, Iran from March to August 2014. Vitam...

full text

O-24: Increased Homocysteinein PCOS Affects Oocyte and Embryo Quality

Background: The biochemical characteristics of the follicular fluid (FF) play essential role in oocyte quality, the subsequent fertilization potential and embryo development. The oocyte quality and metabolism largely depends on follicular microenvironment. Present study aimed to investigate the relationship between oocyte quality and FF homocysteine (Hcy) level in women undergoing to IVF treatm...

full text

O-26: Effects of Recombinant-LH Supplementation on The Proteomic Profile of Follicular Fluid from Poor Responder Patients: Focus on Follicular Growth Factors and Oocyte Maturity Markers

Background Poor and fragmentary data was available regarding the effects of recombinant-LH (r-LH) in in-vitro granulosa and theca cells of human origin. No data was available from in vivo studies regarding the effects of r-LH supplementation on SCF,EGF,ERK-1/2 and AKT-1 pathways in the follicular fluid of older-poor-responder women undergoing IVF cycle. Evidence from in-vitro and animal studies...

full text

N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin.

Polycystic ovary syndrome (PCOS) is associated with low-quality oocytes. The aim of the present study was to investigate the effects of metformin (MET), N-acetylcysteine (NAC) and their combination on follicular fluid parameters, oocytes and embryo quality in PCOS patients. A prospective randomised placebo-controlled pilot study on 60 Iranian women with PCOS (aged 25-35 years) undergoing intrac...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 3

pages  31- 31

publication date 2013-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023